Phathom Pharmaceuticals annual net profit margin
2023
2024
2025
Phathom Pharmaceuticals Net Profit Margin Growth & History (PHAT)
Phathom Pharmaceuticals's net profit margin was −126.35% for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −126.35% | +478.75 pp |
| 2024 | 2024-12-31 | −605.09% | +28953.85 pp |
| 2023 | 2023-12-31 | −29,558.94% | — |
Phathom Pharmaceuticals quarterly net profit margin
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −23.67% | +168.24 pp |
| Q1 2026 | 2026-03-31 | −52.09% | +278.62 pp |
| Q4 2025 | 2025-12-31 | −36.73% | +214.26 pp |
| Q3 2025 | 2025-09-30 | −60.55% | +462.80 pp |
| Q2 2025 | 2025-06-30 | −191.91% | +1056.67 pp |
| Q1 2025 | 2025-03-31 | −330.71% | +4002.55 pp |
| Q4 2024 | 2024-12-31 | −250.98% | +11416.17 pp |
| Q3 2024 | 2024-09-30 | −523.34% | — |
| Q2 2024 | 2024-06-30 | −1,248.58% | — |
| Q1 2024 | 2024-03-31 | −4,333.26% | — |
| Q4 2023 | 2023-12-31 | −11,667.16% | — |
Phathom Pharmaceuticals net profit margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Phathom Pharmaceuticals's net profit margin increased from −29,558.94% to −126.35%, a change of +29432.60 percentage points. The latest reported quarter, Q2 2026, shows −23.67%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
